Janney Montgomery Scott LLC Has $1.59 Million Position in Jazz Pharmaceuticals PLC $JAZZ

Janney Montgomery Scott LLC cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,955 shares of the specialty pharmaceutical company’s stock after selling 255 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Jazz Pharmaceuticals were worth $1,587,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its holdings in Jazz Pharmaceuticals by 14.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after buying an additional 293,360 shares during the period. JPMorgan Chase & Co. lifted its holdings in Jazz Pharmaceuticals by 4.7% during the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company’s stock worth $206,343,000 after buying an additional 74,501 shares during the period. Fuller & Thaler Asset Management Inc. lifted its holdings in Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after buying an additional 391,660 shares during the period. Swedbank AB lifted its holdings in Jazz Pharmaceuticals by 10.0% during the 1st quarter. Swedbank AB now owns 1,102,143 shares of the specialty pharmaceutical company’s stock worth $136,831,000 after buying an additional 100,211 shares during the period. Finally, Perpetual Ltd lifted its holdings in Jazz Pharmaceuticals by 60.2% during the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company’s stock worth $118,212,000 after buying an additional 357,784 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on JAZZ shares. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. The Goldman Sachs Group lifted their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Friday, August 29th. Royal Bank Of Canada lifted their price objective on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a research report on Thursday, August 28th. Morgan Stanley lifted their price objective on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective for the company. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $178.93.

Insider Activity

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 3,500 shares of the company’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $140.00, for a total value of $490,000.00. Following the transaction, the director directly owned 408,826 shares in the company, valued at $57,235,640. This represents a 0.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 11,500 shares of company stock worth $1,525,280. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Down 2.0%

Shares of NASDAQ:JAZZ opened at $135.43 on Friday. The stock has a market cap of $8.22 billion, a price-to-earnings ratio of -20.12, a PEG ratio of 8.32 and a beta of 0.28. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The business’s 50 day moving average is $125.87 and its 200 day moving average is $115.65.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the previous year, the firm earned $5.30 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.